Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells
Figure 6
Virus HA vaccination at late stages of A20HA brain tumor progression stimulates activation of residual HA-specific CD4+ T cells in vivo. ((a), (b)) Percent of CD4+Thy-1.1+ T cells (upper) and intensity of CD44 expression (lower) by cells isolated from (a) cervical lymph nodes and (b) spleens from separated asymptomatic (As) and symptomatic (Sy) mice on day 18 after the adoptive transfer. HA-specific CD4+Thy1.1+ T cells were injected i.v. to A20HA brain tumor-bearing mice on day 5 after i.c. tumor inoculation. Virus HA-Vac was delivered i.p. on day 15 after the adoptive transfer. Individual cervical lymph nodes and spleens of asymptomatic and symptomatic mice (three mice per group) were analyzed by FACS for CD4+CD44+Thy1.1+ T cells. A20HA + T cells + HA-Vac, mice that received A20HA tumor cells, HA-specific CD4+Thy1.1+ T cells and virus HA-Vac; A20HA + T cells, mice that received A20HA tumor cells and HA-specific CD4+Thy1.1+ T cells; T cells + HA-Vac, mice that received HA-specific CD4+Thy1.1+ T cells and virus HA-Vac; T cells, mice that received only HA-specific CD4+Thy1.1+ T cells. Data are represented as the mean ± SD, . .
